Business Wire

Announcing Fungible Storage Cluster with Support for VMware vSphere

Share

Fungible Inc., the dynamic composable infrastructure company, today announced a new release of Fungible Storage Cluster® (FSC) 4.1, providing support for VMware vSphere® environments requiring high-performance.

Virtual machines provide unparalleled flexibility in managing complex and changing compute environments. Workloads running in virtualized environments can have varied storage requirements. For demanding workloads, Fungible’s high-performance all-flash array based on NVMe/TCP is now certified for vSphere and available for VMware virtualized environments. The latest release (4.1) will now enable customers to experience the superior manageability of vSphere combined with the high performance of Fungible’s Storage Cluster.

"NVMe/TCP enables vSphere customers to accelerate their storage performance while leveraging existing investments and lowering complexity,” said Marc Fleischmann, Cloud CTO, VMware, “Through collaboration with innovative companies such as Fungible, VMware continues to build a world-class ecosystem of technology partners that offer our customers flexibility and choice to meet their business requirements.”

Customers can plug FSC storage into their ESXi servers with NVMe/TCP and get what appears to be local storage. The resulting performance is nearly identical to local storage even though it is a shared resource providing economic benefits to match the performance benefits.

“VMware vSphere is the virtualization infrastructure of choice for a variety of mission-critical, performance-sensitive workloads in the data center,” said Eric Burgener, Research Vice President, Infrastructure Systems, Platforms and Technologies at IDC. “As IT organizations deploy more workloads that require accelerated compute and storage, the use of composable, disaggregated infrastructure (CDI) like that available from Fungible will be deployed more often to enable the more efficient use of these types of resources in VMware environments. IDC expects that the CDI market overall will top $4.8 billion by 2025.”

“VMware has long led the drive to improve flexibility and utilization of data center infrastructure. Now with the latest release of our vSphere certified Fungible Storage Cluster, VMware users can further enhance their ability to tune demanding workloads to get the utmost performance and flexibility,” said Pradeep Sindhu, Co-Founder and CDO of Fungible. “Trade-offs of flexibility versus performance are no longer required. Pairing VMware with NVMe/TCP for storage access with our DPU-powered Storage Cluster allows VMware customers to address the performance requirements of today's modern applications.”

With FSC, vSphere users may also see storage cost savings since FSC’s erasure coding provides robust data protection which can be less expensive than traditional RF1 or RF2 replication. Additionally, Fungible’s composable data infrastructure provides flexibility to compose storage to meet current needs and recompose it to adapt to changing needs providing outstanding investment protection.

To learn more about the new FSC 4.1 and the VMware vSphere certification and how you can get more value and performance from your VMware vSphere resources click here or contact sales@fungible.com.

About Fungible:

Silicon Valley-based Fungible, the world’s premier dynamic composable infrastructure company, creates solutions to cloudify the world’s data centers by utilizing the Fungible DPU™ to connect CPUs, GPUs, and storage via NVMe/TCP over standard IP/Ethernet networks. Fungible aims to revolutionize the performance, economics, reliability and security of scale-out data centers. Visit Fungible to learn more. Follow us on Twitter and LinkedIn.

Fungible and Fungible FSC are registered trademarks of Fungible, Inc. VMware and vSphere are registered trademarks or trademarks of VMware, Inc. in the United States, and other jurisdictions. This article may contain hyperlinks to non-VMware websites that are created and maintained by third parties who are solely responsible for the content on such websites.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jennifer Bell
Fungible, Inc.
(669) 292-5522
press@fungible.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye